DESCOVY 200 MG — DIN 02454416
EMTRICITABINE : 200 MG TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) : 10 MG · GILEAD SCIENCES CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is DESCOVY?
DESCOVY 200 MG contains EMTRICITABINE : 200 MG TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02454416, held by GILEAD SCIENCES CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 03-Jun-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DESCOVY used for?
Treatment of HIV-1 Infection: DESCOVY is indicated in combination with other antiretrovirals (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg. HIV-1 Pre-Exposure Prophylaxis (PrEP): DESCOVY is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing ≥ 35 kg, excluding individuals at risk from receptive vaginal sex.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Emtricitabine And Tenofovir Alafenamide cost around the world?
Emtricitabine And Tenofovir Alafenamide is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Belgium publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Belgium | public | 22 | 22 | EUR███.██ |
| South Africa | single exit price | 16 | 20 | ZAR███.██ |
| United Arab Emirates | public | 4 | 4 | AED███.██ |
| Bahrain | retail (max) | 3 | 4 | BHD███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Saudi Arabia | public | 4 | 4 | SAR███.██ |
| Australia | ex-manufacturer | 2 | 3 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 2 | 3 | CZK███.██ |
| Iceland | max wholesale | 2 | 3 | ISK███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| United States | acquisition | 1 | 2 | USD███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
72 pack listings across 63 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Emtricitabine And Tenofovir Alafenamide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Emtricitabine And Tenofovir Alafenamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Emtricitabine And Tenofovir Alafenamide — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GILEAD SCIENCES CANADA INC | 2 | 2 | DESCOVY | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Each bottle contains 30 tablets and a silica gel desiccant and is closed with a child-resistant closure. |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Emtricitabine And Tenofovir Alafenamide |
|---|---|
| ATC code | J05AR17 |
| AHFS class | 08:18.08.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02454416 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2454416 |
| Brand name | DESCOVY |
| Generic / active ingredient | EMTRICITABINE : 200 MG TENOFOVIR ALAFENAMIDE (TENOFOVIR ALAFENAMIDE HEMIFUMARATE) : 10 MG |
| Market authorization holder | GILEAD SCIENCES CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | J05AR17 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05AR |
| Current status | MARKETED |
| Status date | 03-Jun-2016 |
| Original market date | 2016-06-03 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DESCOVY | 25 MG | TABLET | GILEAD SCIENCES CANADA INC | MARKETED | 02454424 |
2 · Same class — other molecules in ATC J05AR
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tenofovir Disoproxil And Emtricitabine | AG-EMTRICITABINE / TENOFOVIR DISOPROXIL FUMARATE · APO-EMTRICITABINE-TENOFOVIR · AURO-EMTRICITABINE-TENOFOVIR · JAMP EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +6 more | 10 | 9 | Yes |
| Emtricitabine, Tenofovir Disoproxil And Efavirenz | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATRIPLA · AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · +5 more | 9 | 5 | Yes |
| Lamivudine And Abacavir | APO-ABACAVIR-LAMIVUDINE · APO-ABACAVIR-LAMIVUDINE TABLETS · AURO-ABACAVIR/LAMIVUDINE · JAMP ABACAVIR / LAMIVUDINE · +5 more | 9 | 4 | Yes |
| Zidovudine And Lamivudine | APO-LAMIVUDINE-ZIDOVUDINE · AURO-LAMIVUDINE/ZIDOVUDINE · COMBIVIR · JAMP LAMIVUDINE / ZIDOVUDINE · +1 more | 5 | 3 | Yes |
| Lopinavir And Ritonavir | KALETRA | 4 | 3 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Bictegravir | BIKTARVY | 2 | 2 | Yes |
| Emtricitabine And Tenofovir Alafenamide | DESCOVY | 2 | 2 | Yes |
| Emtricitabine, Tenofovir Alafenamide And Rilpivirine | ODEFSEY | 1 | 1 | Yes |
| Darunavir And Cobicistat | PREZCOBIX | 1 | 1 | Yes |
| Emtricitabine, Tenofovir Alafenamide, Elvitegravir And Cobicistat | GENVOYA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J05AB | Acyclovir · Brincidofovir · Cidofovir · Famciclovir · Ganciclovir · +3 more | 143 | 55 |
| J05AF | Abacavir · Adefovir Dipivoxil · Didanosine · Emtricitabine · Entecavir · +7 more | 71 | 39 |
| J05AH | Neuraminidase Inhibitors · Oseltamivir · Zanamivir | 33 | 16 |
| J05AX | Baloxavir Marboxil · Bulevirtide · Enfuvirtide · Fostemsavir · Inosine Pranobex · +5 more | 19 | 14 |
| J05AE | Amprenavir · Atazanavir · Darunavir · Fosamprenavir · Indinavir · +5 more | 75 | 14 |
| J05AG | Delavirdine · Doravirine · Efavirenz · Etravirine · Nevirapine · +1 more | 22 | 10 |
| J05AJ | Cabotegravir · Dolutegravir · Elvitegravir · Raltegravir | 12 | 6 |
| J05AP | Asunaprevir · Boceprevir · Daclatasvir · Dasabuvir, Ombitasvir, Paritaprevir And Ritonavir · Elbasvir And Grazoprevir · +8 more | 22 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DESCOVY called?
The same molecule, Emtricitabine And Tenofovir Alafenamide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Biktarvy | Latin | Iceland, Saudi Arabia |
| HETRIPCO | Latin | South Africa |
| Odefsey | Latin | Australia, Czechia, Iceland |
| Adco Emtevir | Latin | South Africa |
| Hetemcit | Latin | South Africa |
| DUOTEMTRIC | Latin | South Africa |
| EMTEWIN | Latin | South Africa |
| Emtroc Tablets | Latin | South Africa |
| GENVOYA Film-coated Tablet | Latin | Saudi Arabia |
| Odefsey (Abacus Medicine) CPR.PELLIC. | Latin | Luxembourg |
| Prepetam | Latin | South Africa |
| TABEX | Latin | South Africa |
| Tafbin | Latin | South Africa |
| Tavirant | Latin | South Africa |
| Temecit | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.